PORxin: Additional Phase IIb data

Additional data from the double-blind, Canadian Phase IIb TRIUMPH trial in 92 patients showed that PRX302 non-significantly improved IPSS from baseline to 12 months vs. placebo (placebo-adjusted improvement of 2.8 points, p>0.05). PRX302 also non-significantly improved Qmax at 12 months vs. placebo (placebo-adjusted improvement of 2.2 mL/second, p=0.072). There were no erectile function side effects reported during the 12 months following treatment with PRX302. Patients received 3 µg/mL PRX302 injected into the prostate at a volume equivalent to 20% of the total prostate volume or placebo. ...